Summary of COVID-19 GB0139 studies

1. Gaughan et al., An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)

41 patient GB0139 late treatment RCT: 40% higher mortality (p=0.7) and 100% longer hospitalization.
RCT 41 hospitalized COVID-19 pneumonitis patients showing inhaled GB0139, a galectin-3 inhibitor, was well-tolerated with no treatment-related serious adverse events. There were greater rates of decline in inflammatory markers (CRP, LDH, neutrophil-lymphocyte ratio) and coagulation markers in the GB0139 group, but no significant differences in clinical outcomes.
Jan 2023, American J. Respiratory and Critical Care Medicine, https://www.atsjournals.org/doi/10.1164/rccm.202203-0477OC, https://c19p.org/gaughan